ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0545

Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis

Stylianos Georgiadis1, Marion Pons2, Simon Horskjær Rasmussen2, Merete Hetland3, Louise Linde2, Daniela DiGuiseppe4, Brigitte Michelsen5, Johan Karlsson Wallman6, Tor Olofsson7, Karel Pavelka8, Jakub Závada8, Bente Glintborg9, Anne Gitte Loft10, Catalin Codreanu11, Daniel Melim12, Diogo Esperança Almeida13, Tore K. Kvien14, Vappu Rantalaiho15, Ritva Peltomaa16, Bjorn Gudbjornsson17, Olafur Palsson18, Ovidiu Rotariu19, Ross MacDonald19, Ziga Rotar20, Katja Perdan-Pikmajer20, Karin Laas21, Florenzo Iannone22, Adrian Ciurea23, Mikkel Ostergaard24 and Lykke Oernbjerg1, 1Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, 2Rigshospitalet Glostrup, Glostrup, Denmark, 3Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 4Karolinska Institutet, Stockholm, 5Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, 6Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, 7Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, 8Institute of Rheumatology and Charles University, Praha, Czech Republic, 9DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, 10Aarhus University Hospital and Aarhus University, Horsens, Denmark, 11University of Medicine and Pharmacy, Bucharest, Romania, 12Hospital Egas Moniz, Lisbon, Portugal, 13Hospital de Braga, Braga, Portugal, 14Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 15Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, 16Helsinki University Hospital and University of Helsinki, Helsinki, Finland, 17Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 18University of Iceland and Skåne University Hospital, Reykjavik, Iceland, 19University of Aberdeen, Aberdeen, United Kingdom, 20University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 21East-Tallinn Central Hospital, Tallinn, Estonia, 22Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, 23University Hospital Zurich, Zürich, Switzerland, 24Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark

Meeting: ACR Convergence 2024

Keywords: Disease Activity, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: In observational studies, several longitudinal methods have been proposed to impute missing data of an individual by using the available information of the same individual at other time points. An alternative approach is to apply a cross-sectional method which imputes missing values of an individual at a particular time point based on the available information from other individuals at that time point. We aimed to compare selected cross-sectional methods for imputing disease activity in longitudinal observational data of patients with axial spondyloarthritis (axSpA).

Methods: Data on patients with axSpA from 10 European registries were used to conduct a simulation study. Patients initiating a tumour necrosis factor inhibitor or an interleukin-17A inhibitor as their first biological disease-modifying anti-rheumatic drug between 2017 and 2021 were included. Disease activity was assessed by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS) and the achievement of low disease activity (LDA; ASDAS< 2.1) at baseline, 6 and 12 months. In a simulation setting, we applied 9 single cross-sectional imputation methods, divided into three groups: mean, regression and hot deck imputation (Table 1), while complete case analysis was applied as a comparator method to imputation. The performance of each imputation method was evaluated via relative bias, i.e., the difference between the estimated and the true value, divided by the true value, for mean ASDAS and derived proportion of patients achieving LDA. Analyses were carried out for a sample size of 1,000, where 60% of data were missing at random, and 1,000 simulated datasets were generated. Simulations were conducted separately for each of the three time points.

Results: Data from 8,583 patients who had at least one available ASDAS registration at any time point were included in the simulations. Mean (standard deviation) ASDAS at baseline, 6 months and 12 months were 3.7 (1.1), 2.0 (1.0) and 1.8 (0.9), respectively. Overall, the simulation results showed that performance of the imputation methods was better for missing follow-up data than for missing baseline data, and higher bias was observed when assessing achievement of ASDAS LDA than for mean ASDAS (Figure 1). When estimating the mean ASDAS, all predictive mean hot deck methods had a relative bias < 2% for baseline data, while mean and regression methods resulted in a bias >5%. For missing values at both follow-up time points, all imputation methods had a bias < 5%. The lowest bias was observed for linear regression and predictive mean hot deck methods (< 1%) at 6 months, and for predictive mean hot deck (< 2%) at 12 months. Regarding performance for estimating ASDAS LDA, all imputation methods resulted in bias > 5% at baseline, while predictive mean hot deck methods consistently resulted in a bias < 5% at both follow-up time points.

Conclusion: This study adds knowledge regarding possible methods for handling missing data in observational research. Of the 9 cross-sectional imputation methods, the three hot deck single imputation methods using predictive mean matching showed the highest robustness and thus constitute the suggested approaches.

Supporting image 1

Table 1. Summary of the cross-sectional imputation methods

Supporting image 2

Figure 1. Mean ASDAS (upper panel) and corresponding proportion of patients achieving ASDAS low disease activity (lower panel) in simulated data of sample size 1,000, where 60% of data were missing at random. Black horizontal lines represent the true values for each time point. True values were determined on the complete case data, i.e., pooled registrations with complete data for ASDAS at a particular time point. Methods requiring only categorical covariates (conditional M-SI and conditional HD-SI) did not produce results at all time points due to insufficient number of individuals in classes in the simulated datasets. ASDAS: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein; CCA: complete case analysis; HD-SI: hot deck single imputation; LR-SI: linear regression single imputation.


Disclosures: S. Georgiadis: Novartis, 5, UCB, 5; M. Pons: Novartis, 5, UCB, 5; S. Rasmussen: Novartis, 5; M. Hetland: AbbVie/Abbott, 5, 12, Paid to my institution, no personal fee, Bristol-Myers Squibb(BMS), 5, 12, Paid to my institution, no personal fee, Eli Lilly, 5, 12, Paid to my institution, no personal fee, Medac, 6, 12, Paid to my institution, no personal fee, Merck/MSD, 5, 12, Paid to my institution, no personal fee, Novartis, 5, 6, Pfizer, 5, 6, 12, Paid to my institution, no personal fee, Sandoz, 5, 6, 12, Paid to my institution, no personal fee, UCB, 6, 12, Paid to my institution, no personal fee; L. Linde: Novartis, 5, UCB, 5; D. DiGuiseppe: None; B. Michelsen: Novartis, 5, 6; J. Karlsson Wallman: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Eli Lilly, 5, Novartis, 5, Pfizer, 5; T. Olofsson: MSD, 12, Co-author of paper without financial support, UCB, 12, Co-author of paper without financial support; K. Pavelka: AbbVie/Abbott, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, Merck/MSD, 6, Novartis, 6, Pfizer, 6, UCB, 6; J. Závada: AbbVie/Abbott, 1, AstraZeneca, 6, Eli Lilly, 6, Sanofi, 6, Sobi, 6, UCB, 6; B. Glintborg: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, Pfizer, 5, Sandoz, 5; A. Loft: AbbVie/Abbott, 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, UCB, 2, 6; C. Codreanu: AbbVie/Abbott, 2, 6, Amgen, 2, 6, Boehringer-Ingelheim, 2, 6, Eli Lilly, 2, 6, Ewopharma, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Sandoz, 2, 6; D. Melim: None; D. Esperança Almeida: None; T. Kvien: AbbVie/Abbott, 1, 2, 5, Bristol-Myers Squibb(BMS), 5, Galapagos, 5, Gilead, 2, Grünenthal, 6, Janssen, 2, 6, Novartis, 2, 5, Pfizer, 2, 5, Sandoz, 2, 6, UCB, 2, 5; V. Rantalaiho: AbbVie/Abbott, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 1, Novartis, 6, Viatris, 6; R. Peltomaa: None; B. Gudbjornsson: None; O. Palsson: None; O. Rotariu: None; R. MacDonald: None; Z. Rotar: None; K. Perdan-Pikmajer: None; K. Laas: AbbVie/Abbott, 6, Janssen, 6, Novartis, 6; F. Iannone: AstraZeneca, 2, GSK, 2, Pfizer, 2, UCB, 2; A. Ciurea: None; M. Ostergaard: Abbott, 2, 5, 6, BMS, 6, Centocor, 5, Merck, 2, 6, Mundipharma, 6, Pfizer, 2, 5, 6, Roche, 2, UCB Pharma, 2, 6; L. Oernbjerg: Novartis, 5, UCB, 5.

To cite this abstract in AMA style:

Georgiadis S, Pons M, Rasmussen S, Hetland M, Linde L, DiGuiseppe D, Michelsen B, Karlsson Wallman J, Olofsson T, Pavelka K, Závada J, Glintborg B, Loft A, Codreanu C, Melim D, Esperança Almeida D, Kvien T, Rantalaiho V, Peltomaa R, Gudbjornsson B, Palsson O, Rotariu O, MacDonald R, Rotar Z, Perdan-Pikmajer K, Laas K, Iannone F, Ciurea A, Ostergaard M, Oernbjerg L. Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/missing-data-in-observational-studies-investigating-cross-sectional-single-imputation-methods-for-assessing-disease-activity-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/missing-data-in-observational-studies-investigating-cross-sectional-single-imputation-methods-for-assessing-disease-activity-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology